Pharmaceutical | Tokio X'press - Part 99

💊Notice Regarding Implementation of New Drug Discovery Program “JOINUS” Using Drug Repositioning Compound Libraries by Astellas Pharma, Mitsubishi Tanabe Pharma and Daiichi Sankyo

Wednesday October 11th, 2017By Tokio X'press JPN, Pharmaceutical Astellas

💊Kyowa Hakko Kirin Announces Discontinuation for Developing ARQ 197 (Tivantinib)

Friday October 6th, 2017By Tokio X'press JPN, Pharmaceutical kyowa-kirin

💡ChromaJean to Launch at Takeda’s Shonan Research Center 2017年10月2日

💡ChromaJean to Launch

Monday October 2nd, 2017By Tokio X'press JPN, Pharmaceutical ChromaJean Inc

💡ChromaJean to Launch

💊Bristol-Myers Squibb Company, Opivo® (generic name: niborumab), approved as Fda as a treatment for hepatocellular cancer patients with treatment history with sorafenib 20170927

💊Bristol-Myers Squibb

Friday September 29th, 2017By Tokio X'press FDA, JPN ONO

💊Bristol-Myers Squibb

💊Mitsubishi Tanabe Pharma Corporation] Notice regarding acquisition of manufacturing and sales approval for Rupafin tablets Allergy treatment agent with new mechanism of action shows strong effectiveness with dual action (anti-PAF and antihistamine action) 20170927

💊Mitsubishi Tanabe Pha

Thursday September 28th, 2017By Tokio X'press JPN, Pharmaceutical mt-pharma

💊Mitsubishi Tanabe Pha